albumin - publications

Predict more albumin - ligand interactions now!


1. Korean J Intern Med. 2012 Mar;27(1):13-9. Epub 2012 Feb 28.

Albumin for end-stage liver disease.

Lee JS.

Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of
Medicine, Goyang, Korea.

Albumin has been widely used in patients with cirrhosis in an attempt to improve
circulatory and renal functions. The benefits of albumin infusions in preventing
the deterioration in renal function associated with large-volume paracentesis,
spontaneous bacterial peritonitis, and established hepatorenal syndrome in
conjunction with a vasoconstrictor are well established. While some of these
indications are supported by the results of randomized studies, others are based
only on clinical experience and have not been proved in prospective studies. The
paucity of well-designed trials, the high cost of albumin, the lack of a
clear-cut survival benefit, and fear of transmitting unknown infections make the
use of albumin controversial. The recent development of the molecular adsorbent
recirculating system, an albumin dialysis, is an example of the capacity of
albumin to act by mechanisms other than its oncotic effect. Efforts should be
made to define the indications for albumin use, the dose required, and predictors
of response, so that patients gain the maximum benefit from its administration.

PMCID: PMC3295983
PMID: 22403494 [PubMed - in process]